Terrance P. Coyne
Known title: EVP & CFOCIK: 0001814876
Associated companies
Transaction History
| RPRX | ▼ Sell | Open Market | 9,230 | $541K | 8/13/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 1,772 | $105K | 8/13/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 11,002 | $0 | 8/5/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 64,399 | $3.5M | 5/26/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 24,263 | $0 | 5/6/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 32,916 | $1.6M | 4/28/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 1,875 | $93K | 4/28/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 1,875 | $91K | 4/1/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 32,916 | $1.6M | 4/1/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 32,916 | $1.5M | 3/23/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 1,875 | $85K | 3/23/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 22,487 | $1.0M | 3/2/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 10,429 | $490K | 3/2/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 1,292 | $60K | 3/2/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 583 | $27K | 3/2/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 1,875 | $85K | 2/23/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 32,916 | $1.5M | 2/23/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 26,626 | $0 | 2/11/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 19,076 | $826K | 2/4/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 1,087 | $47K | 2/4/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 108,759 | $4.7M | 2/3/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 6,195 | $265K | 2/3/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 5,843 | $246K | 2/2/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 102,581 | $4.3M | 2/2/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 65,832 | $2.6M | 1/20/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 3,750 | $148K | 1/20/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 65,832 | $2.5M | 1/2/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 3,750 | $144K | 1/2/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 65,832 | $2.5M | 12/15/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 3,750 | $144K | 12/15/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 65,832 | $2.6M | 12/1/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 3,750 | $149K | 12/1/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 55,146 | $2.1M | 11/24/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 10,686 | $406K | 11/24/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 3,126 | $121K | 11/24/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 624 | $24K | 11/24/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 65,844 | $2.6M | 11/17/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 3,750 | $147K | 11/17/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 6,168 | $0 | 11/5/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 3,696 | $0 | 8/6/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 48,646 | $0 | 5/8/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 37,500 | $1.2M | 8/10/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 37,500 | $1.2M | 8/9/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 37,500 | $1.2M | 7/13/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 37,500 | $1.2M | 7/12/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 24,500 | $1.1M | 11/8/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 5,500 | $237K | 11/2/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 30,000 | $1.3M | 8/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.